Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500

Wyeth is now a wholly owned subsidiary of Pfizer73 enrolled

Overview

Upon completion of participation in the 6108A1-500 study, subjects will be asked to consent for this duration of immunity study to provide up to two additional blood samples. SBA \& IgG testing will be done on these samples taken at 6 \& 12 months. The sites participating in this duration of immunity study are the same sites participating in the 6108A1-500 study.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Blood SamplingPROCEDURE

Blood draws at 6 and 12 months following end of 6108A1-500 trial.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 25 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Completed study 6108A1-500 (three doses administered and visit 9 completed). Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding time. * Any clinically significant chronic disease that, in the investigators judgment may be worsened by blood draw.

Locations (3)

Unnamed facility

Herson, Queensland, Australia

Unnamed facility

North Adealaide, South Australia, Australia

Unnamed facility

Perth, Western Australia, Australia

Outcomes

Primary Outcomes

Immunogenicity at 6 and 12 months post 6108A1-500 study.

Time frame: 6 and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.